A Need for Further Education on Buprenorphine in Pain Medicine
With the ongoing opioid epidemic in the United States there has been a strong transition towards utilizing multi-modal analgesia, interventional procedures, and non-opioid medications when managing acute and chronic pain. There has also been an increased interest in utilizing buprenorphine. Buprenorphine is a novel long-acting analgesic with partial mu-opioid agonist activity that can be utilized for analgesia as well as opioid use disorder. Buprenorphine also has a unique set of side effects as well pharmacodynamic and pharmacokinetic properties that require special attention, especially if these patients require future surgical interventions. Given the increased interest in this medication we believe that there needs to be increased education and awareness regarding this medication amongst physicians, specifically pain management physicians and trainees.
1. Cohen SP, Vase L, Hooten WM. Chronic pain: an update on burden, best practices, and new advances. Lancet. 2021;397(10289):2082-2097. doi:10.1016/s0140-6736(21)00393-7
2. Volkow N, Benveniste H, McLellan AT. Use and Misuse of Opioids in Chronic Pain. Annu Rev Med. 2018;69(1):451-465. doi:10.1146/annurev-med-011817-044739
3. Edinoff AN, Akuly HA, Hanna TA, et al. Selective Serotonin Reuptake Inhibitors and Adverse Effects: A Narrative Review. Neurol Int. 2021;13(3):387-401. doi:10.3390/neurolint13030038
4. Robinson C, Dalal S, Chitneni A, et al. A Look at Commonly Utilized Serotonin Noradrenaline Reuptake Inhibitors (SNRIs) in Chronic Pain. Health Psychol Res. 2022;10(3):32309. doi:10.52965/001c.32309
5. Dalal S, Chitneni A, Berger AA, et al. Buprenorphine for Chronic Pain: A Safer Alternative to Traditional Opioids. Health Psychol Res. 2021;9(1):27241. doi:10.52965/001c.27241
6. Poliwoda S, Noor N, Jenkins JS, et al. Buprenorphine and its formulations: a comprehensive review. Health Psychol Res. 2022;10(3):37517. doi:10.52965/001c.37517
7. Kohan L, Potru S, Barreveld AM, et al. Buprenorphine management in the perioperative period: educational review and recommendations from a multisociety expert panel. Reg Anesth Pain Med. 2021;46(10):840-859. doi:10.1136/rapm-2021-103007
8. Gress K, Charipova K, Jung JW, et al. A comprehensive review of partial opioid agonists for the treatment of chronic pain. Best Practice & Research Clinical Anaesthesiology. 2020;34(3):449-461. doi:10.1016/j.bpa.2020.06.003
9. Webster L, Gudin J, Raffa RB, et al. Understanding Buprenorphine for Use in Chronic Pain: Expert Opinion. Pain Medicine. 2020;21(4):714-723. doi:10.1093/pm/pnz356
10. Edinoff AN, Nix CA, Hollier J, et al. Benzodiazepines: Uses, Dangers, and Clinical Considerations. Neurol Int. 2021;13(4):594-607. doi:10.3390/neurolint13040059
11. Center for Substance Abuse Treatment. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Treatment Improvement Protocol (TIP) Series 40. DHHS Publication No. (SMA) 04-3939. Substance Abuse and Mental Health; 2004.
12. Michaud K, Plunkett H, Kohan L. Buprenorphine treatment recommendations for patients with opioid use disorder. ASRA News. 2021;46(4). doi:10.52211/asra110121.064